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Aim: The astrocyte-elevated gene-1 (AEG-1, also known as metadherin) is associated with various aspects of tumour malignancy;
however, little knowledge is available related to the role of AEG-1 in ductal and lobular carcinomas. The aim of this study was to
investigate the relationship of AEG-1 with the prognostic parameters in invasive ductal and lobular carcinomas.
Materials and methods: This study was conducted on a total of 72 paraffin-embedded breast tumour samples. They consisted of 61
ductal and 11 lobular carcinomas. Breast tumour samples were stained for AEG-1. The prognostic parameters were compared with the
results of AEG-1 stains.
Results: We observed that more ductal carcinoma types than lobular carcinoma types resulted in high AEG-1 staining, whereas low
AEG-1 staining occurred more in lobular carcinomas than in ductal carcinomas (P = 0.05). A significant negative correlation was also
found between HER-2 (r = –0.30, P = 0.019) and AEG-1 (r = –0.804, P = 0.003) in lobular carcinomas. A significant relationship was
found between increasing numbers of positive lymph nodes and AEG-1 in ductal carcinoma cases (P = 0.05).
Conclusion: These results are consistent with previous reports of the role of AEG-1 in tumour progression. AEG-1 could be a useful
marker for the development of new treatments and resistant hormonal therapy.
Key words: Ductal carcinomas, lobular carcinomas, AEG-1, prognostic parameters

1. Introduction
Breast cancer is the most commonly diagnosed type of
cancer, and the leading cause of death from cancer, among
women in the United States (1). There were 192,370 new
cases of breast cancer and 40,170 people died from this
disease in 2009 (1). Moreover, in more than 40% of the
women diagnosed with breast cancer, it had developed
to metastasis (2). Breast cancer survival is linked to early
detection, genetic predisposition, and timely appropriate
treatment.
More recently, human epidermal growth factor receptor
2 (HER-2/neu), oestrogen (ER), and progesterone (PR)
receptors have, with increasing importance, influenced the
management of the malignancy. Prognosis is related to a
variety of clinical, pathological, and molecular features,
which include classic prognostic factors, histological type,
grade, tumour size, and lymph node metastases (3).
* Correspondence: havvaerdem@duzce.edu.tr

With an established positive correlation of ER
and PR with the degree of tumour differentiation, the
determination of ER and PR status on biopsy specimens
prior to therapeutic intervention is advocated as standard
practice (4).
HER-2 status and hormone receptors are the most
important predictive markers in breast cancer. Their
assessment is generally performed on resected primary
tumours in order to select patients eligible for hormone
and HER-2 directed therapies (5–10).
Breast cancer is a heterogeneous disease with a diverse
biology and natural history, for which there are a variety
of treatment options. Therefore, it is important for the
prevention of breast cancer to find reliable biomarkers that
may be used to individualise patient prognosis.
The astrocyte-elevated gene-1 (AEG-1), also known as
metadherin (MTDH), was initially identified as a human
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immunodeficiency virus (HIV-1) and tumour necrosis
factor (TNF), an inducible gene in primary human foetal
astrocytes (11,12). Partly due to the phenomenon by which
chromosome 8q22 gains functions independently in poor
prognosis in breast cancer, the human AEG-1 gene is
located at 8q22 (11,13). Its genomic amplification has also
been found in diverse cancers, including breast cancer, in
comparison with their normal counterparts (14,15).
Recent studies have demonstrated that AEG-1
increases the invasiveness of malignant cells, favouring
tumour genesis, metastasis, and neovascularisation, and
that up-regulation in epithelial cells inhibits apoptosis
(16). In addition, AEG-1 is frequently overexpressed in
highly proliferative breast cancer and high-grade lesions
(17,18).
In this study, we have shown there is a relationship
between AEG-1 and prognostic parameters and tumour
types.
2. Materials and methods
This study was conducted on a total of 72 paraffinembedded breast tumour samples, which were
histopathologically diagnosed at the Department of
Pathology of the Düzce University Hospital between 2005
and 2010. All the diagnoses were made by 2 pathologists,
following the pathology of the World Health Organization
Classification of Tumours. The samples consisted of 61
ductal and 11 lobular carcinomas. The age distribution
of the patients ranged from 31 to 83 years (mean: 53.85
± 1.573). The tumour size distribution was as follows: less
than 2 cm in diameter in 28 patients, from 2 to 5 cm in 36
patients, and more than 5 cm in 8 patients.
In all cases, the histological diagnosis and prognostic
parameters were confirmed by corresponding
paraffin-embedded materials, and when necessary,
immunohistochemical study panels were carried out
according to the most recent World Health Organization
(WHO) classification.
The tumour grade of invasive carcinoma was classified
according to the Scarff–Bloom–Richardson system (19).
Based on the frequency of cell mitosis, tubule formation,
and nuclear pleomorphism, invasive carcinoma was
graded as grade 1 (low), 2 (moderate), or 3 (high). The
presence of lymph node metastases was reviewed for each
patient. Prognostic parameters were compared with the
results of AEG-1 stains.
2.1. Immunohistochemistry
Among the haematoxylin and eosin (H&E)-stained
slides, one suitable paraffin block was chosen. For AEG-1,
Genetex brand 2F11C3 clone was used and it was diluted
at a ratio of 1:200. The degree of immunostaining was
reviewed and scored independently by 2 observers, based
on both the proportion of positively stained tumour cells

94

and the intensity of staining. The proportion of tumour
cells was scored as follows: 0 (no positive tumour cells),
1 (<10% positive tumour cells), 2 (10%–50% positive
tumour cells), and 3 (>50% positive tumour cells). The
intensity of staining was graded according to the following
criteria: 0 (no staining), 1 (weak staining = light yellow), 2
(moderate staining = yellow brown), and 3 (strong staining
= brown). The staining index was calculated from the
staining intensity score and proportion of positive tumour
cells. Using this method of assessment, we evaluated the
expression of AEG-1 in normal tubular epithelia and
malignant lesions by determining the staining index,
which was scored as 0, 1, 2, 3, 4, 6, and 9. A staining index
score of ≥4 was used to define tumours as having high
AEG-1 expression and ≤3 as having low expression of
AEG-1 (16) (Figures 1 and 2).
2.2. Statistical analysis
The likelihood chi-square and Mann–Whitney U tests
were used when comparing associations of AEG-1, ER,
PR, and HER-2 immunoreactivity with tumour subtype.
In addition, Spearman rank correlation analysis, the
likelihood chi–square test, or Mann–Whitney U analysis
(whichever was deemed appropriate in each case) was used
to evaluate the relationship between prognostic factors and
the degree of staining, and the relation of staining results
to each other. The level of significance was determined
to be 0.05 (P = 0.05). Analyses were performed using the
statistical package PASW (version 18).
3. Results
We observed that more ductal carcinoma types than
lobular carcinoma types resulted in high AEG-1 staining,
whereas low AEG-1 staining occurred more in lobular
carcinomas than in ductal carcinomas (P = 0.05) (Table 1).
No significant relationship was found between the subtype
and ER, PR, or HER-2 (P = 0.343, 0.532, and 0.639,
respectively) (Table 2). The relationships among ER, PR,
HER-2, and prognostic parameters were evaluated in cases
of ductal carcinomas and showed a significant correlation
between increasing ER and PR (r = 0.551, P = 0.0001). There
was a significant negative correlation between ER and the
histological grade (r = –0.30, P = 0.019). No significant
correlation was found between AEG-1 and the intraductal
component (P = 0.398) (Table 3). The relationships among
ER, PR, HER-2, and prognostic parameters were evaluated
in cases of lobular carcinomas and showed a significant
negative correlation between HER-2 (r = –0.30, P = 0.019)
and AEG-1 (r = –0.804, P = 0.003) using the Spearman
rank correlation analysis. There was no significant
correlation between AEG-1 and lymphovascular (LVS)
invasion in ductal carcinoma cases (P = 0.354). However,
there was a significant relationship between increasing
number of positive lymph nodes (PLNs) and AEG-1 in
ductal carcinoma cases (P = 0.05) (Table 4). No significant
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Figure 1. AEG-1 stain in ductal carcinomas, low and high stain (right side), 200×.

Figure 2. AEG-1 stain in lobular carcinomas, low and high stain (right side), 200×.
Table 1. Distribution of AEG-1 stain and subtypes.
Low

High

Total

n

%

n

%

Ductal

26

2.6

35

7.4

61 (100%)

Lobular

8

72.7

3

27.3

11 (100%)

Total

34

47.2

38

52.8

72 (100%)
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Table 2. Distribution of subtype and ER, PR, and HER-2.

ER
PR
HER-2

Type

n = 72

Mean (%)

Std. deviation

Std. error mean

Ductal

61

48.11

35.498

4.545

Lobular

11

35.91

36.319

10.951

Ductal

61

50.18

35.121

4.497

Lobular

11

41.82

37.435

11.287

Ductal

61

1.62

1.128

0.144

Lobular

11

1.45

1.128

0.340

Table 3. Distribution of AEG-1 and intraductal component.
Intraductal component

Low

High

Total

n

%

n

%

Negative

5

55.6

4

44.4

9 (100%)

Positive

21

40.4

31

59.6

52 (100%)

Total

26

42.6

35

57.4

61 (100%)

Table 4. Distribution of PLN and AEG-1.
Ductal carcinomas

Low

High

n

%

n

%

Negative

18

52.9

16

47.1

34 (100%)

Positive

8

29.6

19

70.4

27 (100%)

Total

26

42.6

35

57.4

61 (100%)

correlation was found between AEG-1 and LVS invasion
(P = 0.385) and PLNs (P = 0.205) in lobular carcinoma
cases. There was no significant correlation between the
intraductal component and ER (P = 0.383) and HER2 (P = 0.088) in ductal carcinomas, whereas there was a
significant negative correlation with PR (P = 0.035).
4. Discussion
The development of target therapy has changed the
prognosis of patients, both in adjuvant and metastatic
settings (18,20). Although new therapies have significantly
improved the survival rate of cancer patients, a large
number of patients still succumb to this disease, mostly
due to metastasis and chemoresistance. In view of this
fact, the discovery of novel targets and strategies for the
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Total

development of effective anticancer therapies is urgently
required.
MTDH/AEG-1 is expressed in low levels or is absent
in most normal human breast tissue, but was found to
be frequently overexpressed in breast cancer cell lines or
breast tumours (12,20– 23). In this study, AEG-1 staining
found more expression in ductal carcinomas than in
lobular carcinomas.
Using breast tumour samples collected in the United States
and in China, 2 independent analyses revealed strikingly
similar patterns of MTDH/AEG-1 expression and clinical
association (24,25). MTDH/AEG-1 was abundantly expressed
in 44%–47% of the primary tumours and significantly
correlated with the clinical stage, tumour size, lymph node
spread, distant metastasis, and poor survival (23–26).
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Dağlar et al. found that tumour histological grade
was an independent factor in cancer-specific survival and
disease-free survival (27).
Tokatlı et al. found that axillary nodal status and HER2/neu were the most important determining factors for
prediction of disease-free survival in breast cancer patients
(28).
MTDH/AEG-1 expression was not correlated with other
common clinicopathological parameters, including age,
oestrogen receptor, progesterone receptor, HER-2, and p53
status. No significant difference in MTDH/AEG-1 expression
was observed in basal or luminal subtypes of breast tumours
(23). Multivariate analysis suggested that MTDH/AEG-1
expression is an independent prognostic indicator for the
survival of patients with breast cancer (29–31).
In this study, AEG-1 staining found a significant
negative correlation between HER-2 (in lobular carcinoma
cases) and a significant relationship between increasing
positive LN (in ductal carcinomas cases). No significant
correlation was found between AEG-1 and lymphovascular
invasion, age, ER, PR, or size.
Li et al. demonstrated the lack of influence of hormone
therapy and chemotherapy on ER and PR status (18),
while Idirisinghe et al. showed a correlation between ER
and PR loss and hormone therapy (8). Sequential breast
cancer biopsies have shown that ER levels are reduced
slightly with intervening endocrine therapy, while PR
levels decrease more dramatically, with up to half of the
tumours completely losing PR expression, when resistance
develops (25). Few studies have shown a shorter survival
rate among women with ER-negative metastatic and locally
recurrent tumours, regardless of the primary tumour ER
status (32,33). Whether, and how, the loss of PR affects
the clinical course of ER-positive/PR-negative metastatic
tumours remains to be clarified (32). However, as with

earlier studies, there seems to be no correlation between
receptor status and histological type of the tumours
(14,16,32–34).
This study has found significant correlation between
AEG-1 staining and subtype (ductal and lobular). There
was no significant correlation between AEG-1 and ER or
PR, but a significant relationship was observed between
increasing positive LN and AEG-1 in ductal carcinoma
cases. For this reason, AEG-1 may be considered to be
high in cases of decreased ER and PR.
Statistical analysis of the relationship between AEG1 staining and the clinical characteristics of patients
presented a significant correlation of AEG-1 expression
with clinical stage, lymph node metastasis, and LVS
invasion, further supporting a potential role of AEG1 in tumour angiogenesis (19). The reason may be that
AEG-1 is commonly overexpressed in highly proliferative
lesions of breast cancer (12,13). This could be related to
other significant independent factors such as tumour size
and lymph-node status. This study found a significant
relationship between increasing positive LN and AEG1 in ductal carcinoma cases. In addition, we observed a
significant negative correlation between HER-2 and AEG1 in lobular carcinomas. Whereas high AEG-1 staining
occurred more in ductal carcinomas than in lobular
carcinomas, low AEG-1 staining was more frequent in
lobular carcinomas than in ductal carcinomas.
We feel there is a need for further studies of a larger
scope in order to shed more light on the cause of these
findings.
In conclusion, AEG-1 staining could be important in
demonstrating the role of AEG-1 in histological subtype
and tumour progression. In addition, AEG-1 could be a
useful marker for the development of new treatments and
resistant hormonal therapy.
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